# A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

> **NCT00189761** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc**

## Conditions studied

- Bone Marrow Transplantation
- Graft Versus Host Disease
- Graft-Vs-Host Disease
- Graft-Versus-Host Disease

## Interventions

- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00189761
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2006-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189761, "A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00189761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*